SCHEMBL3341019

SCHEMBL3341019

O=C(c1ccc(Br)cc1F)N1CCC(F)(F)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.46
CNR1 P21554 1/20 0.44
CPS1 P31327 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
NR3C1 P04150 1/20 0.40
GPR183 P32249 3/20 0.40
PIK3C3 Q8NEB9 1/20 0.40
CCKBR P32239 1/20 0.40
NAMPT P43490 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 2/20 0.38
NPC1 O15118 1/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
SPR P35270 1/20 0.38
PLAT P00750 1/20 0.38
CYP2C9 P11712 1/20 0.37
PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1423630 0.88 DGAT1 (0.51) DGAT1CPS1SMN1; SMN2GPR183CCKBR
SCHEMBL30033227 0.85 SMN1; SMN2 (0.50) SMN1; SMN2NR3C1GPR183PIK3C3NAMPT
SCHEMBL951383 0.81 CNR1 (0.42) CNR1CPS1NR3C1PIK3C3NAMPT
SCHEMBL30791513 0.79 CCKBR (0.56) DGAT1CNR1CPS1SMN1; SMN2CCKBR
SCHEMBL1424241 0.79 CCKBR (0.56) DGAT1CNR1CPS1SMN1; SMN2CCKBR
SCHEMBL643698 0.79 CPS1 (0.60) DGAT1CPS1CCKBRKDM4EALDH1A1
SCHEMBL24185210 0.78 HPGD (0.57) GPR183NAMPTLMNA
SCHEMBL969401 0.78 CCKBR (0.58) DGAT1CNR1CPS1SMN1; SMN2CCKBR
SCHEMBL16093639 0.76 SMN1; SMN2 (0.46) CNR1SMN1; SMN2ALDH1A1GAACYP2C9
SCHEMBL968813 0.75 MAPT (0.57) DGAT1CNR1CPS1NPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722741-B2 Biphenyloxyacetic acid derivatives for the treatment of respiratory disease ASTRAZENECA AB (SE) 2014-05-13 US disclosed
EP-1784388-B3 BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE ASTRAZENECA AB (SE) 2012-09-05 EP disclosed
US-20120178732-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease LUKER TIMOTHY JON (GB) 2012-07-12 US disclosed
US-20100160285-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease ASTRAZENECA AB (SE) 2010-06-24 US disclosed
US-7737135-B2 Biphenyloxyacetic acid derivatives for the treatment of respiratory disease ASTRAZENECA AB (SE) 2010-06-15 US disclosed
EP-1784388-B1 BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE ASTRAZENECA AB (SE) 2009-11-04 EP disclosed
US-20080132480-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease ASTRAZENECA AB (SE) 2008-06-05 US disclosed
EP-1784388-A1 BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE AstraZeneca AB (SE) 2007-05-16 EP disclosed
WO-2006021759-A1 BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE ASTRAZENECA AB (SE) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178732-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease CYP26A1, CYP1A1, GPBAR1 DGAT1 1488/4885CNR1 645/4885CPS1 390/4885
US-20100160285-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease CYP26A1, CYP1A1, GPBAR1 DGAT1 1488/4885CNR1 645/4885CPS1 390/4885
US-20080132480-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease CYP26A1, CYP1A1, GPBAR1 DGAT1 1488/4885CNR1 645/4885CPS1 390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.